Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate vs. Delayed Ipilimumab Following Sipuleucel-T in mCRPC
NCT01804465Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Apr 2014
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of California, San Francisco. Started Apr 2014; status: completed.
02
Drugs
ipilimumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01804465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01804465.